Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2018 Nov 29:12:ed86.
doi: 10.3332/ecancer.2018.ed86. eCollection 2018.

Precision oncology: as much expectations as limitations

Vitor Fiorin Vasconcellos  1 , Leandro Machado Colli  2 , Ahmad Awada  3 , Gilberto de Castro Junior  1
Affiliations
Editorial

Precision oncology: as much expectations as limitations

Vitor Fiorin Vasconcellos et al. Ecancermedicalscience. .

Abstract

It is encouraging to witness the recent price reduction and expanded access to next generation sequencing platforms, the increasing number of investments and publications on new targets and respective targeted drugs, as well as the worldwide excitement with anti-cancer personalised therapies. This editorial aims to highlight the limitations regarding the small proportion of solid cancers potentially eligible for the use of molecular-based targeted drugs until now. It also covers the expected clinical benefits in refractory patients treated by matched therapies, and detailed cost-effectiveness analysis of the use of DNA sequencing analysis oncology practice in an academic and large-scale community.

Keywords: DNA; molecular diagnostic techniques; molecular targeted therapy; precision medicine; sequence analysis.

PubMed Disclaimer

References

    1. Tannock IF, Hickman JA. Limits to personalized cancer medicine. N Engl J Med. 2016;375(13):1289–1294. - PubMed
    1. Marquart J, Chen EY, Prasad V. Estimation of the percentage of US patients with cancer who benefit from genome-driven oncology. JAMA Oncol. 2018;4(8):1093–1098. - PMC - PubMed
    1. Burki TK. Larotrectinib in TRK fusion-positive cancers. Lancet Oncol. 2018;19(4):e187. - PubMed
    1. Schwaederle M, Zhao M, Lee JJ, et al. Association of biomarker-based treatment strategies with response rates and progression-free survival in refractory malignant neoplasms: a meta-analysis. JAMA Oncol. 2016;2(11):1452–1459. - PubMed
    1. Schwaederle M, Zhao M, Lee JJ, et al. Impact of precision medicine in diverse cancers: a meta-analysis of phase II clinical trials. J Clin Oncol. 2015;33(32):3817–3825. - PMC - PubMed

Publication types

LinkOut - more resources